Bispecific antibodies are an advanced class of biologics engineered to recognise and bind two distinct antigens or epitopes simultaneously. By bridging cellular interactions or co‑targeting molecular pathways, Bio X Cell's in vivo-ready bispecifics offer a powerful strategy for immune cell redirection, dual‑pathway blockade, payload delivery, and enhanced selectivity.
In drug discovery and translational research, bispecific antibodies are increasingly used to:
- Redirect T cells or NK cells for targeted cytotoxicity
- Engage multiple immune checkpoints
- Block redundant or compensatory signalling pathways
- Improve tumour specificity and reduce off‑target effects
- Explore novel immune‑therapeutic mechanisms in oncology, autoimmunity, and infectious disease
Bio X Cell’s curated bispecific antibody portfolio offers multiple formats and is designed to support the rapid development and validation of innovative therapeutic concepts, offering high‑purity, in vivo-grade reagents backed by the quality standards researchers expect.
- Anti-mouse bispecific antibodies: purpose-built, in vivo-ready bispecific reagents optimised for murine studies, closely modeled on clinical formats to support reliable mechanism‑of‑action and efficacy insights.
- Anti-human bispecific biosimilars: high-fidelity biosimilar bispecifics engineered to reflect therapeutic antibodies, enabling precise benchmarking and translational validation from discovery through development.
- Custom bispecific engineering: tailored bispecific antibody design backed by expert scientific guidance and scalable manufacturing solutions, accelerating advancement of bispecific pipelines.
Bio X Cell’s bispecific solutions
- Mouse-specific bispecific antibodies provide researchers the tools they need for mouse models, without having to invest in expensive humanised mice.
- Biosimilars of clinical bispecifics enable research comparisons with therapeutic formats
- Bispecifics are dual-target validated, high purity and in vivo ready, allowing researchers to run studies immediately without waiting for custom constructs
- Consistent, low endotoxin, reproducible bispecifics reduce experimental variability, helping researchers generate cleaner data faster, lowering risk and accelerating go/no-go decisions
- Researchers can use ready to ship bispecifics or choose custom services.
| Target pair | Therapeutic analogue | Species | Applications |
|---|---|---|---|
| CD3 x BCMA | Teclistamab | Human | Preclinical modeling of bispecific T-cell engager activity in multiple myeloma. |
| CD3 x GPRC5D | Talquetamab | Human | Evaluating dual-targeting strategies for resistant myeloma and T-cell redirection. |
| EGFR x MET | Amivantamab | Human | Studying receptor crosstalk, ligand competition, and resistance mechanism in epithelial tumors. |
| CD3 x CD20 | Epcortimab* | Mouse | Investigating dual B-cell targeting and T-cell engagement in syngeneic lymphoma models. |
| PD-1 x VEGF | Ivonescimab* | Mouse | Modeling immune checkpoint and angiogenic pathway interplay in mouse tumor studies. |
*Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above.
Material for download
Bio X Cell bispecific antibodies brochure
Bio X Cell bispecific antibodies product flyer
Products
Note: product availability depends on country - see product detail page.
| Details | Cat number & supplier | Size | Price |
| InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R001mg · Bio X Cell | SIM0067-R001mg Bio X Cell |
1 mg |
£410.00
1 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R001mg · Bio X Cell | SIM0069-R001mg Bio X Cell |
1 mg |
£423.00
1 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-1MG · Bio X Cell | CPB502-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) CPB501-5MG · Bio X Cell | CPB501-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R005mg · Bio X Cell | SIM0069-R005mg Bio X Cell |
5 mg |
£1635.00
5 mg
view
|
| Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) CPB501-1MG · Bio X Cell | CPB501-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control CPB500-5MG · Bio X Cell | CPB500-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| Bispecific mouse IgG2a (LALA-PG)-scFv, kappa isotype control CPB500-1MG · Bio X Cell | CPB500-1MG Bio X Cell |
1 mg |
£3550.00
1 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R001mg · Bio X Cell | SIM0081-R001mg Bio X Cell |
1 mg |
£423.00
1 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R005mg · Bio X Cell | SIM0081-R005mg Bio X Cell |
5 mg |
£1635.00
5 mg
view
|
| InVivoSIM anti-human CD3 x BCMA (Teclistamab Biosimilar) SIM0067-R005mg · Bio X Cell | SIM0067-R005mg Bio X Cell |
5 mg |
£1587.00
5 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-5MG · Bio X Cell | CPB502-5MG Bio X Cell |
5 mg |
£9993.00
5 mg
view
|
| InVivoSIM anti-human CD3 x GPRC5D (Talquetamab Biosimilar) SIM0069-R025mg · Bio X Cell | SIM0069-R025mg Bio X Cell |
25 mg |
£5707.00
25 mg
view
|
| InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar) SIM0081-R025mg · Bio X Cell | SIM0081-R025mg Bio X Cell |
25 mg |
£5707.00
25 mg
view
|
| Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) CPB502-25MG · Bio X Cell | CPB502-25MG Bio X Cell |
25 mg |
£42591.00
25 mg
view
|
